Treatment and prevention of viral hepatitis in pregnancy.
Dionne-Odom J, Cozzi GD, Franco RA, Njei B, Tita ATN.
Am J Obstet Gynecol. 2022 Mar;226(3):335-346. doi: 10.1016/j.ajog.2021.09.002. Epub 2021 Sep 10.
Daclatasvir.
[No authors listed]
2022 Feb 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
Sofosbuvir.
[No authors listed]
2022 Feb 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
Zepatier.
[No authors listed]
2022 Feb 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
Urticaria and hepatitis.
Cribier B.
Clin Rev Allergy Immunol. 2006 Feb;30(1):25-9. doi: 10.1385/CRIAI:30:1:025.
Late presentation of chronic viral hepatitis for medical care: a consensus definition.
Mauss S, Pol S, Buti M, Duffell E, Gore C, Lazarus JV, der Grient HL, Lundgren J, Mozalevskis A, Raben D, Schatz E, Wiktor S, Rockstroh JK; European consensus working group on late presentation for Viral Hepatitis Care.
BMC Med. 2017 May 3;15(1):92. doi: 10.1186/s12916-017-0856-y.
Biomarkers in Detection of Hepatitis C Virus Infection.
Woo J, Choi Y.
Pathogens. 2024 Apr 17;13(4):331. doi: 10.3390/pathogens13040331.
Treatment of Chronic Hepatitis C Virus Using Direct Acting Antivirals in Geriatric Egyptian Patients.
Elkadeem M, Shoman SR.
Recent Adv Antiinfect Drug Discov. 2021;16(2):157-165. doi: 10.2174/2772434416666210716123909.
Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice.
Marascio N, Rotundo S, Quirino A, Matera G, Liberto MC, Costa C, Russo A, Trecarichi EM, Torti C.
World J Gastroenterol. 2022 Mar 28;28(12):1226-1238. doi: 10.3748/wjg.v28.i12.1226.
New treatments for genotype 1 chronic hepatitis C - focus on simeprevir.
Kanda T, Nakamoto S, Wu S, Yokosuka O.
Ther Clin Risk Manag. 2014 May 24;10:387-94. doi: 10.2147/TCRM.S50170. eCollection 2014.
